Prenatal Tdap immunization and risk of maternal and newborn adverse events
Introduction
Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis immunization (Tdap) administered during pregnancy conveys passive pertussis immunity to newborns via transplacental transmission of maternal pertussis antibodies [1], [2], [3], [4], [5], [6]; thus, several countries recommend Tdap during every pregnancy, including closely spaced pregnancies [7], [8], [9]. Despite international efforts to prevent infant pertussis through maternal Tdap, prenatal uptake remains sub-optimal [10], [11], [12], [13], [14], due in part to concerns about safety [15], [16]. While generally accepted as safe, widespread prenatal Tdap requires careful scrutiny to establish the safety for the mother and newborn.
Tdap has not been associated with clinically significant harms for the fetus or neonate such as preterm birth, small for gestational age, stillbirth, low birth weight, or congenital anomalies [17]. Similarly, there is no evidence of increased risk of serious adverse events in pregnancy, with the exception of unreplicated findings of increased chorioamnionitis risk from one retrospective study [17], [18]. Previous non-experimental studies have been limited by small sample size, unclear immunization timing, and confounding due to comparing guideline-adherent immunized versus non-adherent unimmunized populations. Given that a strong understanding of the safety of Tdap during pregnancy may be central to increasing uptake, additional studies are needed.
Furthermore, considerable uncertainty persists about the optimal timing of prenatal Tdap administration. The CDC recommends administration at any time during pregnancy, though preferably between gestational weeks 27–36 [19] to maximize maternal antibody response and passive antibody transfer; other countries recommend administration during the second [8] or third trimesters [9] to improve immunization coverage for preterm deliveries. Safety studies which account for the timing of immunization are limited [17].
To examine the safety of Tdap administration during pregnancy, we conducted a large-scale, cohort study comparing the risks of adverse outcomes in the infant and mother associated with Tdap and examined the impact of timing of Tdap administration on safety.
Section snippets
Methods
This administrative insurance claims-based cohort study was approved by the Institutional Review Board of the University of North Carolina at Chapel Hill. Analyses were performed using SAS 9.4 (SAS Institute, Cary NC).
Results
We identified 1,079,034 women (mean age = 29.2 years, SD 5.4 years) with deliveries meeting our study criteria (eFig. 1). Of these women, 148,817 (13.8%) received Tdap during pregnancy, and an additional 59,040 (5.5%) women received Tdap postpartum. The percentage of pregnant women receiving Tdap increased over time; cohort characteristics are shown in Table 1.
Discussion
In this cohort of 1,079,034 pregnant women in the U.S., serious maternal and infant adverse reactions following immunization were rare; for example, only 1 of 207,857 immunized women experienced anaphylaxis, and we detected no cases of GBS within 42 days after Tdap receipt. Twelve prenatally-vaccinated women were later diagnosed with encephalopathy, although all cases occurred during the delivery hospitalization or following delivery, obscuring whether the encephalopathy was associated with the
Conflict of interest
Dr. Layton receives unrestricted salary support from the Center for Pharmacoepidemiology in the UNC Department of Epidemiology; current member companies include GlaxoSmithKline, Merck, and UCB. Dr. Weber served on Speakers' Bureaus and as a vaccine consultant (Merck, Pfizer). Dr. Becker-Dreps has received investigator-initiated research funds from Pfizer for an unrelated study on pneumococcal vaccines.
Acknowledgements
This project was funded by a grant from the US National Institute of Allergy and Infectious Disease (5R21AI115205). The database infrastructure used for this project was funded by the Department of Epidemiology, UNC Gillings School of Global Public Health; the Cecil G. Sheps Center for Health Services Research, UNC; the CER Strategic Initiative of UNC’s Clinical & Translational Science Award (UL1TR001111); and the UNC School of Medicine. S.B.-D. is supported by Grant 2015213 from the Doris Duke
References (38)
- et al.
Maternal Tdap vaccination: Coverage and acute safety outcomes in the vaccine safety datalink, 2007–2013
Vaccine
(2016) - et al.
Receipt of pertussis vaccine during pregnancy across 7 Vaccine Safety Datalink sites
Prev Med
(2014) - et al.
Adverse events after tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine administered to adults 65 years of age and older reported to the Vaccine Adverse Event Reporting System (VAERS), 2005–2010
Vaccine
(2011) - et al.
The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak
Vaccine
(2010) - et al.
Algorithms for identification of Guillain-Barre Syndrome among adolescents in claims databases
Vaccine
(2013) - et al.
Trends in reasons for non-receipt of influenza vaccination during pregnancy in Georgia, 2004–2011
Vaccine
(2016) - et al.
Predictors of H1N1 vaccination in pregnancy
Am J Obstet Gynecol
(2011) - et al.
Inflammatory responses to trivalent influenza virus vaccine among pregnant women
Vaccine
(2011) - et al.
Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum
J Inf Dis
(2004) - et al.
Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants
Clin Inf Dis: Official Pub Inf Dis Soc Am
(2013)
Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants
The Pediatric infectious disease journal.
Effectiveness of Prenatal Versus Postpartum Tetanus, Diphtheria, and Acellular Pertussis Vaccination in Preventing Infant Pertussis
Clin Inf Dis: Official Pub Inf Dis Soc Am
Cost-Effectiveness of Pertussis Vaccination During Pregnancy in the United States
Am J Epidemiol
A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012–2013
Clin Inf Dis: Official Pub Inf Dis Soc Am
Pertussis and Influenza Vaccination Among Insured Pregnant Women - Wisconsin, 2013–2014
MMWR Morbidity and Mortality Weekly Report
Vaccination with tetanus, diphtheria, and acellular pertussis vaccine of pregnant women enrolled in Medicaid-Michigan, 2011–2013
MMWR Morbidity and Mortality Weekly Report
Cited by (44)
Should French pregnant women be vaccinated against pertussis during pregnancy?
2022, Gynecologie Obstetrique Fertilite et SenologieSystematic review and meta-analysis of the effect of pertussis vaccine in pregnancy on the risk of chorioamnionitis, non-pertussis infectious diseases and other adverse pregnancy outcomes
2022, VaccineCitation Excerpt :Additional cases of chorioamnionitis may lead to a higher frequency of preterm birth, considering that preterm birth is a clinically important consequence of chorioamnionitis [14]. Two of our included observational studies [12,13] and one RCT [33], all of which used no pertussis containing vaccine as a comparator, found no significantly increased risk of neonatal sepsis. The relation between maternal pertussis vaccination and preterm birth was not examined in this study, but of the included studies two RCTs [32,33] with placebo as comparator and two RCTs [27,38] with Td as comparator found no statistically significant association between maternal pertussis vaccination and preterm birth.